natgillin/translations-raw huggingface dataset:
Priloga, Člen 11, naslov in odstavek 1
Annex, Article 11, title and paragraph 1
Glede finančnega pravilnika skupnega podjetja se dogovori upravni odbor, ki ga tudi sprejme.
The IMI Joint Undertaking’s financial regulation shall be agreed and adopted by the Board.
Finančna pravila
Financial Rules
Finančna pravila skupnega podjetja po posvetovanju s Komisijo sprejme upravni odbor.
The IMI Joint Undertaking’s financial rules shall be adopted by the Board after consulting the Commission.
Glej predlog spremembe 17.
See Amendment 17.
Priloga, Člen 11, odstavek 2
Annex, Article 11, paragraph 2
Namen finančnega pravilnika je zagotoviti preudarno in finančno upravljanje skupnega podjetja.
The purpose of the financial regulation is to ensure the sound financial management of the IMI Joint Undertaking.
Namen finančnih pravil je zagotoviti dobro finančno poslovodenje skupnega podjetja.
The purpose of the financial rules is to ensure the sound financial management of the IMI Joint Undertaking.
Priloga, Člen 11, odstavek 3
Annex, Article 11, paragraph 3
Lahko odstopa od okvirne finančne uredbe, če to zahtevajo posebne operativne potrebe skupnega podjetja in po predhodnem posvetovanju s Komisijo .
It may depart from the Framework Financial Regulation where the specific operating needs of the IMI Joint Undertaking so require and subject to prior consultation with the Commission .
Pravila o financiranju skupnega podjetja ne smejo odstopati od uredbe (ES, Euratom) št. 2343/2002, razen kadar to zahtevajo njegove posebne operativne potrebe in po predhodnem soglasju Komisije .
The IMI Joint Undertaking's financial rules may not depart from Regulation (EC, Euratom) No 2343/2002, unless its specific operating needs so require and subject to the prior consent of the Commission .
Priloga, Člen 12, odstavek 5
Annex, Article 12, paragraph 5
Zaključni račun in bilanca stanja za predhodno leto se predložita Računskemu sodišču Evropskih skupnosti.
The annual accounts and balance sheets for the preceding year shall be submitted to the Court of Auditors of the European Communities.
Računsko sodišče lahko opravi revizijo v skladu s standardnimi postopki.
An audit may be executed by the Court of Auditors in accordance with its standard procedures.
Zaključni račun in bilanca stanja za predhodno leto se predložita Računskemu sodišču Evropskih skupnosti in proračunskemu organu .
The annual accounts and balance sheets for the preceding year shall be submitted to the Court of Auditors of the European Communities and to the budgetary authority .
Računovodske izkaze in bilance stanja je treba poslati v vednost obema vejama proračunskega organa.
Accounts and balance sheets need to be sent to the two arms of the budgetary authority for information.
Priloga, Člen 13, odstavek 2, pododstavek 1 a (novo)
Annex, Article 13, paragraph 2, subparagraph 1 a (new)
Izvršni direktor Evropskemu parlamentu predloži letno poročilo o dejavnosti.
The Executive Director shall present the annual activity report to the European Parliament.
V okviru njunega rednega dialoga izvršni direktor Evropskemu parlamentu predloži letno poročilo o dejavnosti.
As part of a regular dialogue with the European Parliament the Executive Director should present the Annual Activity Report to the European Parliament.
Priloga, Člen 14, odstavek 1
Annex, Article 14, paragraph 1
Kadrovski viri se določijo v načrtu delovnih mest, ki se navede v letnem proračunu.
The staff resources shall be determined in the establishment plan to be set out in the annual budget.
Kadrovski viri se določijo v načrtu delovnih mest, ki se navede v letnem proračunu in ki ga Komisija skupaj s predhodnim predlogom proračuna Evropske unije posreduje Evropskemu parlamentu in Svetu .
The staff resources shall be determined in the establishment plan to be set out in the annual budget and to be forwarded by the Commission to the European Parliament and the Council together with the preliminary draft general budget of the European Union.
Kot pri že obstoječih skupnih podjetjih bi morala Komisija skupaj s predhodnim predlogom proračuna objaviti načrt delovnih mest skupnega podjetja za pobudo za inovativna zdravila.
As is the case with the Joint Undertakings already in existence, the IMI JU's establishment plan should be published by the Commission together with the PDB.
Priloga, Člen 14, odstavek 2
Annex, Article 14, paragraph 2
Člani osebja skupnega podjetja so začasni in pogodbeni uslužbenci s pogodbo za določen čas, ki se lahko enkrat podaljša, tako da skupno obdobje znaša največ sedem let.
The members of the staff of the IMI Joint Undertaking shall be temporary agents and contract agents and shall have fixed term contracts extendable once up to a maximum total period of seven years.
Člani osebja skupnega podjetja so lahko zaposleni na podlagi različnih pogodb.
Members of the IMI Joint Undertaking staff may be subject to different forms of contract.
Fleksibilnost mora omogočati določeno svobodo pri izbiri pogodb.
A flexible approach should allow a degree of freedom in the choice of contracts.
Priloga, Člen 17, odstavek 5, točka (a)
Annex, Article 17, paragraph 5, point (a)
(a) mikro, mala in srednja podjetja v smislu priporočila Komisije 2033/361/ES v skladu s posebnimi cilji, ki jim jih je postavil sedmi okvirni program ;
(a) micro, small and medium-sized enterprises within the meaning of Commission Recommendation 2003/361/EC , in accordance with the specific objectives set for them by the Seventh Framework Programme;
Ne zadeva slovenske različice.
Does not affect English version
Težava s prevodom.
Does not affect English version.
Priloga, Člen 21, odstavek 2
Annex, Article 21, paragraph 2
Spremembo tega statuta odobri upravni odbor.
Amendment to these Statutes shall be approved by the Board.
Če takšna sprememba vpliva na splošna načela in cilje tega statuta, jo mora odobriti Svet na podlagi predloga Komisije, kar velja zlasti za vse spremembe člena 1, prve alinee člena 5(2)(c), člena 8(3) in člena 21.
If such amendment affects the overall principals and objectives of these Statutes, in particular any amendment to Article 1, first indent of Article 5(2)(c), Article 8(3) and Article 21 shall be subject to approval by the Council based on a proposal by the Commission.
Če takšna sprememba vpliva na splošna načela in cilje tega statuta, jo mora odobriti Svet na podlagi predloga Komisije in po posvetovanju z Evropskim parlamentom , kar velja zlasti za vse spremembe člena 1, prve alinee člena 5(2)(c), člena 8(3) in člena 21.
If such amendment affects the overall principles and objectives of these Statutes, in particular any amendment to Article 1, the first indent of Article 5(2)(c), Article 8(3) and Article 21 shall be subject to approval by the Council based on a proposal by the Commission, and after consultation of the European Parliament.
O vseh pomembnih spremembah statuta skupnega podjetja se je treba posvetovati z Evropskim parlamentom.
The European Parliament needs to be consulted on any important changes to the JU's statutes.
Priloga, Člen 22, odstavek 3, točka (a)
Annex, Article 22, paragraph 3, point (a)
(a) Vsak udeleženec projekta ostane lastnik intelektualne lastnine, ki se vnese v projekt, in ostane lastnik intelektualne lastnine, ki se pridobi med izvajanjem projekta, razen če se udeleženci projekta medsebojno dogovorijo drugače.
(a) Each participant in a project shall remain the owner of the intellectual property that it introduces into a project, and shall remain the owner of the intellectual property that it generates in a project unless otherwise mutually agreed by the participants in a project.
Pogoji glede pravic dostopa in licenc za intelektualno lastnino, ki se vnese v projekt ali jo udeleženci pridobijo med izvajanjem projekta, se določijo v sporazumu o donaciji in sporazumu o projektu za zadevni projekt.
The terms and conditions of access rights and licenses with regard to the intellectual property introduced into or generated by participants in a project, shall be defined in the Grant Agreement and the Project Agreement of the project concerned.
Udeleženci v projektu morajo določiti morebitne primere intelektualne solastnine, pridobljene med izvajanjem projekta.
Project participants should establish any cases of co-ownership of intellectual property arising from projects.
Priloga, Člen 23 a (novo)
Annex, Article 23 a (new)
Sporazum o gostiteljstvu
Host Agreement
Skupno podjetje in Belgija skleneta sporazum o gostovanju.
A host agreement shall be concluded between the IMI Joint Undertaking and Belgium .
Zaradi doslednosti je treba v statut vključiti tudi običajno klavzulo o sporazumu o gostovanju.
For the sake of consistency, the traditional host agreement clause should also be included in the statutes.
Glej tudi predlog spremembe 6.
See also Amendment 6.
Raziskave in inovacije neposredno prispevajo k blaginji in dobrobiti posameznika in skupnosti.
Research and innovation contribute directly to the prosperity and wellbeing of individuals and society.
Glavni cilj politike za raziskave in tehnološki razvoj je ta, da postane Evropska unija gospodarska moč, ki temelji na prvovrstnem znanju.
The main aim of technological research and development policy is to turn the European Union into a leading knowledge economy.
Evropska unija mora omogočiti optimizacijo sodelovanja na različnih ravneh delovanja, boljšo usklajenost evropske in nacionalnih politik, krepitev strukturnih možnosti, povezovanje raziskovalnih skupin ter povečanje mobilnosti ljudi in idej.
The European Union must make it possible to achieve the greatest possible cooperation at various levels, coordinate European and national policies more effectively, strengthen structural capacity and links between research teams and, finally, enhance the mobility of researchers and ideas.
Skupne tehnološke pobude so instrumenti, opredeljeni v posebnem programu „Sodelovanje“ sedmega okvirnega programa.
Joint technological initiatives (JTIs) are instruments defined in the specific programme 'Cooperation' of the Seventh Framework Programme.
Skupne tehnološke pobude so rezultat dela, ki so ga opravile evropske tehnološke platforme šestega okvirnega programa za združitev javnih in zasebnih subjektov za oblikovanje in izvajanje skupnih raziskovalnih programov na področju raziskav, za katere se zanima industrija.
The JTI are the result of the work accomplished by the European technological platforms (ETP) launched under the Sixth Framework Programme to bring together public and private stakeholders to set up and implement joint research programmes in the field of industrial research.
Nekajkrat so evropske tehnološke platforme dosegle tako velik obseg in pomen, da bo za izvedbo njihovih raziskovalnih programov potrebna mobilizacija velikih javnih in zasebnih sredstev.
In a small number of cases, ETPs have achieved such an ambitious scale and scope that they considerable amounts of public and private investment will have to be mobilised in order to implement their research programmes.
V nasprotju z običajno prakso, ko se iz javnih sredstev vsak posamezni projekt financira posebej, skupne tehnološke pobude zadevajo več raziskovalnih programov, ki imajo skupne strateške raziskovalne cilje.
In contrast to the traditional approach, which involved providing projects with public funding on a case-by-case basis, JTIs are designed for large-scale research programme having joint strategic research objectives.
S tem novim pristopom naj bi se ustvarila kritična masa za evropske raziskave in inovacije, evropska raziskovalna skupnost pa bi se utrdila na najpomembnejših strateških področjih.
This new approach is designed to generate critical mass in terms of European research and innovation by consolidating the activities of the European scientific community in the main strategic areas.
Uskladilo se bo financiranje projektov, zato da se bo lahko hitreje izkoristilo rezultate raziskav.
It will harmonise the funding of projects to ensure that research results can be put to use more swiftly.
Med skupnimi tehnološkimi pobudami bo pobuda za inovativna zdravila financirala vseevropska partnerstva med javnim in zasebnim sektorjem na področju biomedicinskih raziskav.
As one of these JTIs, the innovative medicines initiative (IMI) will finance pan-European public/private partnerships in the field of biomedical research.
Čeprav je Evropska unija vodilna sila na področju številnih tehnologij, pa je soočena s čedalje večjimi izzivi ne samo pri običajnih konkurentih, ampak tudi gospodarstvih v vzponu.
Although the EU is a world leader in many technologies, it needs to address an increasing number of challenges not only from its traditional competitors, but also from the emerging economies.
Skupni programi lahko dajo rezultate, ki jih države članice posamezno ne morejo doseči.
The joint programmes can obtain results which the Member States could not achieve by acting alone.
Prodor indijskega in kitajskega gospodarstva v tehnologije z visoko dodano vrednostjo zahteva od Evropske unije povečanje njenega potenciala na področju inovacij, raziskav in tehnologij.
The emerging strength of the Indian and Chinese economies in the area of high-value-added technology is inducing the European Union to enhance its potential with regard to innovation, research and technology.
Inovacije so eden od ključev do uspeha lizbonske strategije za rast in delovna mesta.
Innovation is one of the keys to the future success of the revised Lisbon Strategy for growth and employment.
Vendar se Evropska unija zdi žrtev paradoksa, ki ji preprečuje, da bi v celoti izkoristila svoj potencial: nesposobnost, da pretvori rezultate inovacij v nove proizvode, patente in delovna mesta; veliko število malih in srednjih inovativnih podjetij, ki imajo težave pri razvoju in uveljavljanju na svetovni ravni.
The EU seems, however, to be a victim of the paradoxical failings which prevent it from exploiting its potential to the full: an inability to convert the fruits of innovation into new products, patents and jobs; a large number of innovative small and medium-sized enterprises (SMEs) which are finding it difficult to grow and succeed at world level.
Natančneje, produktivnost farmacevtskih raziskav in razvoja že tri desetletja upada, medtem ko finančne naložbe neprestano naraščajo.
More particularly, the productivity of pharmaceutical research and development has been declining for three decades, although financial investment has been steadily increasing.
V zadnjih 25 letih so se stroški za raziskave in razvoj novega zdravila dvignili od 54 na 880 milijonov evrov, kar predstavlja povišanje za 11,8 % letno.
In 25 years, the amount of expenditure on research and development per pharmaceutical product placed on the market rose from € 54 million to € 880 million, equivalent to an annual increase of 11.8%.
Druga težava je zvišanje odstotka neuspeha v različnih fazah testiranja novih molekul.
As an additional problem, there has been a rise in the failure rate of various stages of the testing process for new molecules.
Testira se čedalje več molekul, zato da se najde ustrezno molekulo za trženje.
An increasing number of compounds is having to be tested to find one which would could be placed on the market.
Sedmi okvirni program za raziskave za obdobje 2007-2013 je za Evropsko unijo priložnost, da dvigne svojo raziskovalno politiko na raven svojih gospodarskih in socialnih ambicij ter utrdi evropski raziskovalni prostor.
The Seventh Framework Programme for research, which covers the period from 2007-2013, offers the EU an opportunity to bring its research policy into line with its economic and social ambitions by consolidating the European Research Area (ERA).
Za dosego tega cilja želi Komisija povečati letni proračun Evropske unije za področje raziskav ter tako pritegniti več nacionalnih in zasebnih naložb.
To achieve that objective, the Commission wishes to increase the EU's annual research budget and thereby stimulate greater national and private investment.
V času njegovega izvajanja se mora sedmi okvirni program, kar zadeva znanje in raziskave, odzivati tudi na potrebe industrije ter na splošno na potrebe evropske politike.
The implementation of the Seventh Framework Programme must also meet the research and knowledge requirements of industry and of European policy objectives in general.
Evropska komisija, države članice in industrija so se odločile, da združijo svoje moči ter skupaj investirajo v strateške raziskovalne programe.
The Commission, the Member States and industry have decided to join forces by investing together in strategic research programmes.
3) Nov skupni pristop
3) A new joint approach
Skupno podjetje za pobudo za inovativna zdravila je edinstvena pobuda, ki jo skupaj izvajajo Evropska komisija, industrijsko združenje in Evropska zveza združenj farmacevtske industrije (EFPIA).
The IMI is a unique initiative jointly implemented by the Commission and the EFPIA (European Federation for Pharmaceutical Industries and Associations).
Da bi dosegel pomemben napredek in obravnaval zahtevne vidike predkonkurenčnih raziskav in razvoja, ta projekt združuje javni sektor, bolnike, univerze, bolnice ter predstavnike farmacevtske industrije.
It will bring together public authorities, patients, universities, hospitals and representatives of the pharmaceutical industry to enable important progress to be made and address the complex issues involved in pre-competitive research and development.
Skupno podjetje bo razpolagalo z dvema milijardama evrov proračuna za obdobje 2008-2013.
The IMI JU will have a total budget of EUR 2 billion for the period 2008-2013.
Evropska komisija mu je dodelila eno milijardo evrov v okviru sedmega okvirnega programa za raziskave.
The Commission has allocated EUR 1 billion to the IMI JU under the Seventh Framework Programme.
Prispevek Skupnosti bo v celoti nakazan malim in srednjim podjetjem ter univerzam, za raziskave pa ga bo lahko uporabil farmacevtski sektor.
The Community's contribution will be paid in full to SMEs and universities to fund research which could be used by the pharmaceutical industry.
Velike družbe bodo prispevale enako vsoto za taista mala in srednja podjetja ter univerze.
The big pharmaceutical companies will make an equivalent contribution and ensure the involvement of these SMEs and universities.
Skupno podjetje bo tako prispevalo k povečanju zasebnih naložb v raziskave in razvoj, k izboljšanju prenosa znanja med univerzami in podjetji ter vključevanju malih podjetij v evropske raziskave.
The IMI JU will, consequently, help boost private investment in R&D, improve knowledge transfer between universities and firms, and increase the participation of small businesses in the European research sector.
4) Pomembne prednosti
4) Appreciable benefits
Skupno podjetje za pobudo za inovativna zdravila bo spodbujalo razvoj novih znanj, pripomočkov in metod, da bi hitreje založilo trg z ustreznejšimi in varnejšimi zdravili.
The innovative medicines initiative will aim to support the development of new knowledge, new tools and new methods in order to ensure more appropriate and safer medicines reach the market more rapidly.
Prispevalo bo k boljšemu zdravljenju zlasti bolnikov, obolelih za rakom, z možganskimi obolenji, boleznimi metabolizma, vnetji in nalezljivimi boleznimi.
It will lead to better care for patients, particularly those suffering from cancer or cerebral, inflammatory, metabolic or infectious diseases.
Namen skupnega podjetja za pobudo za inovativna zdravila ni predlagati posebnih zdravljenj, ampak prepoznati „ozka grla“ v raziskovalnem in razvojnem procesu, kakršna so nadzor nad zdravili, učinkovitost zdravil, upravljanje znanja, izobraževanje in usposabljanje.
The purpose of the IMI JU is not to produce specific treatments but to identify bottlenecks in the R&D process, including pharmacovigilance, drug efficacy, knowledge management, education and training.
Napredek na teh štirih področjih bo omogočil izboljšanje raziskav za hitrejše odkrivanje in razvoj boljših zdravil, zlasti za zdravljenje zapostavljenih bolezni.
Progress in these four areas will make it possible to improve research with a view to discovering, and speeding up the development of, better medicines, particularly for the treatment of 'neglected diseases'.
Skupinski pristop, ki ga je razvilo skupno podjetje, bo zmanjšal tveganja za mala podjetja ter omogočil hitrejši razvoj proizvodov, zahvaljujoč se dostopu do skupnih infrastruktur, virov in materiala.
The collective approach developed by the IMI will reduce the risks involved for small firms and help them to develop products more swiftly by providing them with access to a common infrastructure, resources and equipment.
Pobuda za inovativna zdravila bo temeljila na skupnem podjetju z nepridobitnim namenom v skladu s členom 171 Pogodbe.
The IMI will involve a non-profit joint undertaking pursuant to Article 171 of the Treaty.
Partnerske skupine (univerze, mala in srednja podjetja, biofarmacevtske družbe, javni sektor, bolniki) bodo tvorili partnerstvo med javnim in zasebnim sektorjem, ki bo dajalo pobude za raziskave.
Groups of partners (universities, SMEs, bio-pharmaceutical companies, public authorities, patients) will form a public-private partnership to propose research initiatives.
Partnerstvo med javnim in zasebnim sektorjem bo imelo najmanj eno univerzo in/ali eno malo in srednje podjetje ter družbo, ki bo član zveze EFPIA.
A public-private partnership shall include at least one university and/or SME, and one EFPIA member company.
Komisija in zveza EFPIA sta skupaj oblikovali program strateških raziskav skupnega podjetja.
The Commission and the EFPIA have together drawn up a strategic research agenda for the IMI.
Dokument vsebuje priporočila, ki se nanašajo na glavna „ozka grla“.
This document contains recommendations concerning the main bottlenecks.
Evropa potrebuje nov pristop k raziskavam na obetavnih področjih za našo konkurenčnost in blagostanje.
Europe needs a new approach to research in areas which offer promising prospects for our competitiveness and well-being.
Predlogi kažejo, da mora Evropska komisija gledati na potrebe Evrope z drugačnega zornega kota.
The proposals show that the Commission must now adopt a fresh approach to addressing Europe's requirements in that field.
Partnerstva med javnim in zasebnim sektorjem odpirajo nove obetavne možnosti za raziskave na farmacevtskem področju, pa tudi za raziskave v drugih sektorjih.
These public-private partnerships offer a new and promising alternative for pharmaceutical research, but also for all other areas of research activities.
Poročevalka se veselih teh novih pristopov.
The rapporteur is pleased that approaches of this kind are being implemented.
Splošni okvir, ki ga je določil predlog Evropske komisije, je bil nekoliko spremenjen, da bi natančneje določili nekatere točke.
Some changes are proposed to the general framework laid down by the Commission proposal in order to clarify certain points.
Delitev pravic intelektualne lastnine bo določena znotraj skupnega podjetja, ki bo določilo tudi, kako urediti morebitne solastnine.
The distribution of intellectual property rights should be decided within the IMI JU, which will determine how any potential co-ownership issues should be resolved.
Mala in srednja podjetja ne smejo biti prikrajšana zaradi koristi drugih, veliko večjih industrij.
The interests of SMEs must not be sacrificed to those of other, bigger sections of the industry.
Treba je bolj upoštevati njihove potrebe ter izvajati ukrepe zato, da se jih razbremeni morebitnih dodatnih administrativnih bremen.
It is an essential pre-requisite, therefore, for the needs of SMEs to be taken more fully into account and for support measures to be taken to reduce any additional administrative burdens which might be imposed on them.
Skupne tehnološke pobude uvaja Sedmi okvirni program
Joint Technology Initiatives (JTIs) are introduced in the Seventh Framework Programme
1 kot nov način oblikovanja javno-zasebnih partnerstev na področju raziskav na evropski ravni.
1 (FP7) as a new way of realising public-private partnerships in research at European level.
Skupne tehnološke pobude izhajajo predvsem iz dela evropskih tehnoloških platform.
JTIs arise primarily from the work of European Technology Platforms (ETPs).